BCNA welcomes pharmacy prescription changes for breast cancer medications
Six key breast cancer drugs are now more affordable thanks to 60-day prescribing. BCNA is pleased to confirm that six common types of hormone blocking therapies such as letrozole, anastrozole and tamoxifen, amongst others, are now able to be prescribed 60-days at a time, saving consumers time and money. “It is especially important that we work to reduce the cost of hormone blocking therapies for breast cancer as some are required for ten years or more after active treatment finishes,” said BCNA Director Policy, Advocacy & Support Services Vicki Durston. “Reducing the ongoing cost of these drugs will start to address financial toxicity and improve equity, especially for those in lower socioeconomic groups who already experience disparities in access to breast cancer care.” BCNA advocated strongly in support of 60-day prescribing last year, alongside other groups such as the Royal Australian College of General Practitioners. Read more via the link https://www.bcna.org.au/latest-news/bcna-news/bcna-welcomes-pharmacy-prescription-changes-for-breast-cancer-medications/ and also refer to the Department of Health and Aged Care information sheet https://www.health.gov.au/sites/default/files/2024-03/savings-with-60-day-prescriptions_0.pdf
